Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the Efficacy and Safety of Apitegromab in Participants With Facioscapulohumeral Muscular Dystrophy (FORGE)
Conditions
Interventions
Apitegromab
Placebo
Start Date
August 1, 2026
Primary Completion Date
June 1, 2028
Completion Date
December 1, 2028
Last Updated
February 27, 2026
NCT06907875
NCT06708468
NCT03458832
NCT06079567
NCT04001582
NCT06547216
Scholar Rock, Inc. Clinical Trials Administration
CONTACT
857-259-3860MedicalInformation@scholarrock.comLead Sponsor
Scholar Rock, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions